Combination drugs and vaccine for glioma with remaining tumor
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a type of brain tumor called glioma that has been treated before with chemotherapy or radiation, and you still have some tumor left (even if it's small).
- Your tumor has a specific gene change (IDH mutation or MGMT methylation).
- You are generally able to take care of yourself (you can walk, do light work, and are not bedridden).
- You have a brain shunt or an Ommaya reservoir (a small device under the scalp to drain fluid).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This study tests a combination treatment for glioblastoma, a type of brain cancer. It includes a personalized vaccine made from your tumor, along with chemotherapy and an immunotherapy drug (anti-PD-1). The goal is to see if this combination helps people with this cancer.
This early trial tries to find which medicines might work best for your specific glioblastoma, by testing drugs on cancer “stem cell” samples. If the test finds promising drug options, it may guide a more personalized treatment approach.
This study tests whether a new drug called MT-125, combined with standard radiation and chemotherapy, is safe and effective for patients with a specific type of brain tumor (glioblastoma) that has a particular genetic feature (MGMT methylation). The goal is to see if this combination helps patients live longer without serious side effects.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.